FilingSEC EDGAR8-K
Quoin Pharmaceuticals Announces $50 Million Private Placement and Positive Interim Clinical Results
· SEC accepted
StagePhase 2/3
Filing content
Quoin Pharmaceuticals entered into a $50 million private placement agreement and reported positive interim Phase 2/3 results for its Netherton Syndrome treatment, QRX003.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…